Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
endometrial cancer
Pharma
In endometrial cancer, Merck and Kelun score with sac-TMT
A phase 3 trial of Merck and Kelun's TROP2 ADC sac-TMT has met its two primary endpoints, providing improvements for endometrial cancer patients.
Kevin Dunleavy
May 18, 2026 11:21am
Merck's Keytruda turns in mixed results in gynecological cancers
Sep 13, 2024 6:05pm
GSK blows Jemperli marching brass against Keytruda with new nod
Aug 1, 2024 3:00pm
Merck's Keytruda snags 40th US indication
Jun 18, 2024 9:32am
Where's Lynparza in AZ's narrow Imfinzi endometrial cancer nod?
Jun 17, 2024 11:24am
Merck's Keytruda misses the mark in endometrial cancer study
May 9, 2024 10:55am
